Close
Enter your
text here

Center for Childhood Cancer Research

Donor-Derived NK Cells Safe and Efficacious in Relapsed and Refractory AML
 Donor-Derived NK Cells Safe and Efficacious in Relapsed and Refractory AML 1024 649 Lauren Dembeck
By: Lauren Dembeck

Researchers have used their approach for growing large numbers of NK cells to allow repeated dosing for a more effective and less toxic treatment.   Outcomes for patients with relapsed and refractory acute myeloid leukemia (R/R AML) have not significantly improved over the last 30 years. For example, a recent study of patients treated with…

Proton Therapy – A New Era of Cancer Therapy for Children
 Proton Therapy – A New Era of Cancer Therapy for Children 1024 683 Abbie Miller
By: Abbie Miller

Proton therapy offers benefits over traditional photon radiation therapy. Using proton therapy, doctors can give more specific, concentrated doses of radiation with less risk and damage to the surrounding tissue. Proton therapy is an advanced type of radiation treatment that uses protons instead of X-rays to kill cancer cells. Our proton therapy center uses the…

Interactions Between Invading Tumor and Lung Cells Permit Metastatic Lung Colonization of Osteosarcoma
 Interactions Between Invading Tumor and Lung Cells Permit Metastatic Lung Colonization of Osteosarcoma 150 150 Lauren Dembeck
By: Lauren Dembeck

Survival signals elicited by lung tissue interactions promote osteosarcoma metastasis and represent a promising target for clinical trials in both human and canine patients.   Osteosarcoma, the most common primary tumor of bone, occurs predominantly in children, teens and young adults. Patient survival largely depends upon the presence or absence of metastasis. Within five years…

Oncolytic Virus Immunotherapy Safe and Tolerable in Children With Relapsed or Refractory Solid Tumors
 Oncolytic Virus Immunotherapy Safe and Tolerable in Children With Relapsed or Refractory Solid Tumors 1024 683 Lauren Dembeck
By: Lauren Dembeck

The overall survival rates for children with childhood cancers is now over 80%; however, for children with relapsed and refractory tumors, the survival rates remain low. “For example, children with relapsed or refractory neuroblastoma have a five-year survival of less than ten percent,” explains Keri A. Streby, MD, director of the Neuroblastoma Program in the…

Is Growth Hormone Replacement Safe Following Central Nervous System Tumors?
 Is Growth Hormone Replacement Safe Following Central Nervous System Tumors? 1024 683 Mary Bates, PhD
By: Mary Bates, PhD

Research suggests the benefits of growth hormone therapy outweigh the risks for pediatric cancer survivors. In a new review paper, researchers from Nationwide Children’s Hospital evaluated the risks and benefits associated with administering growth hormone to pediatric patients after diagnosis of a central nervous system tumor. The authors conclude that the therapy has many important…

Featured Researcher — Meisam Naeimi Kararoudi, DVM, PhD
 Featured Researcher — Meisam Naeimi Kararoudi, DVM, PhD 150 150 Katie Brind'Amour, PhD, MS, CHES
By: Katie Brind'Amour, PhD, MS, CHES

Meisam Naeimi Kararoudi, DVM, PhD, director of the CRISPR/Gene Editing Core and principal investigator in the Center for Childhood Cancer Research at Nationwide Children’s, has taken a winding, international road to his current role at Nationwide Children’s Hospital. From his native Iran to Italy, England, Sweden and the United States, Dr. Naeimi Kararoudi has collected…